Ideggyogyaszati szemle · 2026
[Fremanezumab and erenumab for migraine prophylaxis - real-world data from Hungary].
СтатьяМногоцентровое исследованиеАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balogh Eszter, Áfra Judit, Boór Krisztina, Bozsik György, Csáti Anett, Ertsey Csaba, Héja Máté, Kellermann István, Kerényi Levente, Nagy Ferenc, Nagypál Tamás, Ormayné Kovács Gabriella, Párdutz Árpád, Sinka Boglárka, Székely Mariann, Szok Délia, Tajti János, Zsombók Terézia
Аннотация
BACKGROUND AND PURPOSE: Migraine is a highly prevalent neurological disorder affecting predominantly women and significantly impairing quality of life. The introduction of monoclonal antibodies targeting the calcitonin generelated peptide (CGRP) pathway represents a major advancement in preventive therapy. This study aimed to evaluate the realworld effectiveness of erenumab and fremanezumab in Hungarian migraine patients.
METHODS: In this retrospective multicenter study, data from 12 Hungarian headache centers were collected between May and Az alábbi dokumentumot magáncélra töltötték le az eLitMed.hu webportálról. A dokumentum felhasználása a szerzői jog szabályozása alá esik. December 2024. A total of 200 patients receiving erenumab or fremanezumab were included. Migraine subtype, sex, and treatment characteristics were recorded. The number of monthly migraine days and triptan use were compared between the 3 months prior to treatment initiation and the third month of therapy. Statistical analyses included paired t-tests, Wilcoxon signedrank tests, and permutation tests where appropriate.
RESULTS: Both treatments resulted in a significant reduction in monthly migraine days and triptan use in patients with episodic and chronic migraine (all p < 0.001). In fremanezumab-treated patients, median monthly migraine days decreased from 10.0 to 2.0 in episodic migraine and from 17.5 to 6.0 in chronic migraine. In the erenumab group, mean monthly migraine days decreased from 10.8 to 4.3 (episodic) and from 18.6 to 8.9 (chronic). Triptan use also significantly declined in both groups. Nonresponse was observed in a small proportion of patients. Treatment effectiveness was confirmed in both sexes, although statistical power was limited in male subgroups.
CONCLUSION: Real-world data from Hungarian centers demonstrate that both erenumab and fremanezumab are highly effective in reducing migraine burden and acute medication use within the first three months of therapy. These findings support the use of CGRP-targeting monoclonal antibodies as effective preventive treatments, while highlighting the need for further studies on sex-specific treatment responses.
METHODS: In this retrospective multicenter study, data from 12 Hungarian headache centers were collected between May and Az alábbi dokumentumot magáncélra töltötték le az eLitMed.hu webportálról. A dokumentum felhasználása a szerzői jog szabályozása alá esik. December 2024. A total of 200 patients receiving erenumab or fremanezumab were included. Migraine subtype, sex, and treatment characteristics were recorded. The number of monthly migraine days and triptan use were compared between the 3 months prior to treatment initiation and the third month of therapy. Statistical analyses included paired t-tests, Wilcoxon signedrank tests, and permutation tests where appropriate.
RESULTS: Both treatments resulted in a significant reduction in monthly migraine days and triptan use in patients with episodic and chronic migraine (all p < 0.001). In fremanezumab-treated patients, median monthly migraine days decreased from 10.0 to 2.0 in episodic migraine and from 17.5 to 6.0 in chronic migraine. In the erenumab group, mean monthly migraine days decreased from 10.8 to 4.3 (episodic) and from 18.6 to 8.9 (chronic). Triptan use also significantly declined in both groups. Nonresponse was observed in a small proportion of patients. Treatment effectiveness was confirmed in both sexes, although statistical power was limited in male subgroups.
CONCLUSION: Real-world data from Hungarian centers demonstrate that both erenumab and fremanezumab are highly effective in reducing migraine burden and acute medication use within the first three months of therapy. These findings support the use of CGRP-targeting monoclonal antibodies as effective preventive treatments, while highlighting the need for further studies on sex-specific treatment responses.